NIH will fund seven-year trial of Proscar and Cardura for BPH; Hytrin outperforms Proscar in V-A study.
NIH WILL FUND SEVEN-YEAR BPH DISEASE PROGRESSION THERAPY COMPARISON study with $50 mil. grant, Herbert Lepor, MD, New York University School of Medicine, said at a "Prostate Health Update" meeting in Washington, D.C. Aug. 25. The multicenter trial will randomize approximately 2,800 men to placebo, Pfizer's Cardura (doxazosin), Merck's Proscar (finasteride) and doxazosin in combination with finasteride. The study also is expected to provide important implications of the natural history of benign prostatic hyperplasia.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth